A case of a 65-year-old woman presenting with delayed profound thrombocytopenia 7 days after the use of abciximab (ReoPro) in the setting of percutaneous coronary intervention is described. The patient had normal platelet counts for the first 24 hours after the use of abciximab (ReoPro). She presented with petechiae and profound thrombocytopenia 1 week later. The patient was treated successfully with a platelet transfusion and recovered uneventfully. Profound thrombocytopenia occurs acutely within the first few hours after abciximab (ReoPro) use, so this case was unique in that the profound thrombocytopenia presented 1 week after use of abciximab (ReoPro).
1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/HIa receptor in high risk coronary angioplasty. N Engl J Med330:956-961, 1994
2.
2. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J140:74-80, 2000
3.
3. Dasgupta H, Blankenship JC, Wood GC, et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/Illa receptor inhibitors: A pooled analysis. Am Heart J140:206-211, 2000
4.
4. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation95:809-813, 1997
5.
5. Jenkins LA, Lau S, Crawford M, Keung Y. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation97:1214-1215, 1998
6.
6. Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv52:486-488, 2001
7.
7. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab Readministration: Results of the ReoPro Readministration Registry. Circulation104:870-875, 2001
8.
8. Prescribing information for ReoPro (abciximab), Centocor/Eli Lilly.
9.
9. Rao J, Mascarenhas DA. Successful use of eptibatide as an adjunct to coronary stenting in a patient with abciximabassociated acute profound thrombocytopenia. J Invasive Cardiol13:471-473, 2001
10.
10. Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol12:109-112, 2000
